Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
MCRB Total Non-current Liabilities
All obligations due after more than one year.
Seres Therapeutics, Inc.NASDAQ: MCRB
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 12.9% from a year ago
Total non-current liabilities stood at $71.78M at the end of Q1 FY2026, down 12.9% from a year earlier and down 3.9% from the prior quarter. Over 3 fiscal years it compounded at -33.4% a year.
Context
- Total non-current liabilities amounted to 61.0% of total assets at the end of Q1 FY2026, up 10.8 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -12.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 74.65M USD
- Year-over-year change
- -12.0%
- 4-year CAGR
- -14.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.65M | -12.0% |
| FY2024 | 2024-12-31 | 84.8M | -72.2% |
| FY2023 | 2023-12-31 | 304.8M | +20.8% |
| FY2022 | 2022-12-31 | 252.41M | +78.9% |
| FY2021 | 2021-12-31 | 141.09M | — |
Total Non-current Liabilities vs competitors
How MCRB compares with its peers on the latest reported figures
- MCRB's Mar 2026 total non-current liabilities of $71.78M is the 2nd highest of the 9 companies compared; the peer median is $3.19M.
- Its year-over-year change of -12.9% is the 4th highest of 8, against a peer median of -33.5%.
- Total non-current liabilities amounts to 61.0% of total assets for MCRB, versus a peer median of 6.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $103.28M | +448.1% | — | 154.6% |
| Mar 2026 | $71.78M | -12.9% | -33.4% | 61.0% | |
| Mar 2026 | $20.41M | -11.5% | -9.4% | 7.5% | |
| Mar 2026 | $16.92M | -42.9% | — | 12.7% | |
| Mar 2026 | $5.79M | -33.5% | -39.3% | 11.6% | |
| Mar 2026 | $598K | -95.9% | -66.4% | 1.0% | |
| Mar 2026 | $447.99K | — | +189.2% | 1.5% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K | -2.8% | -32.3% | 4.5% |
| Mar 2026 | $176K | -37.1% | -56.6% | 0.5% | |
| Peer median (excluding MCRB) | $3.19M | -33.5% | -35.8% | 6.0% | |
Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 180M | 163.03M | 127.97M | 30.79M | 45.77M |
| Short-term Investments | 110.7M | 18.31M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 4.75M | 360K |
| Inventory | 0 | 0 | 29.65M | 0 | 0 |
| Other Current Assets | 0 | 13.42M | 17.8M | 3.13M | 3.25M |
| Total Current Assets | 303.63M | 194.76M | 175.41M | 38.67M | 49.38M |
| Property, Plant & Equipment (Net) | 36.15M | 133.97M | 108.03M | 92.44M | 80.12M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 495K | 9.59M | 9.59M | 8.67M | 8.67M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 14.59M | 10.47M | 65.57M | 31K | 31K |
| Total Non-current Assets | 51.23M | 154.02M | 183.19M | 101.14M | 88.82M |
| Total Assets | 354.86M | 348.78M | 358.6M | 139.81M | 138.19M |
| Account Payables | 13.74M | 17.44M | 3.64M | 4.08M | 1.68M |
| Short-term Debt | 0 | 456K | 0 | 0 | 10.39M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 16.82M | 4.26M | 7.73M | 0 | 0 |
| Other Current Liabilities | 21.1M | 34.77M | 59.19M | 17.75M | 4.57M |
| Total Current Liabilities | 82.26M | 85.6M | 98.66M | 41.22M | 19.32M |
| Long-term Debt | 24.64M | 50.59M | 101.54M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 87M | 92.43M | 95.36M | 0 | 0 |
| Other Non-current Liabilities | 11.5M | 1.44M | 16.24M | 1.84M | 2.08M |
| Total Non-current Liabilities | 141.09M | 252.41M | 304.8M | 84.8M | 74.65M |
| Total Liabilities | 223.35M | 338M | 403.46M | 126.03M | 93.98M |
| Common Stock | 92K | 125K | 135K | 173K | 10K |
| Retained Earnings | (614.35M) | (864.51M) | (978.24M) | (978.1M) | (972.4M) |
| Accumulated OCI | (60K) | (12K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 131.51M | 10.78M | (44.86M) | 13.78M | 44.22M |
| Total Debt | 49.21M | 162.59M | 198.78M | 91.64M | 82.97M |
| Net Debt | (130.79M) | (440K) | 70.82M | 60.85M | 37.2M |
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.